Endurance Wealth Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Endurance Wealth Management’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,500	Closed	–	–	673
2022 Q3	$0	Hold	1,500	–	–	﹤0.01%	652
2022 Q2	$0	Hold	1,500	–	–	﹤0.01%	656
2022 Q1	$12K	Hold	1,500	–	–	﹤0.01%	506
2021 Q4	$12K	Hold	1,500	–	–	﹤0.01%	496
2021 Q3	$12K	Hold	1,500	–	–	﹤0.01%	509
2021 Q2	$6K	Hold	1,500	–	–	﹤0.01%	557
2021 Q1	$11K	Hold	1,500	–	–	﹤0.01%	528
2020 Q4	$11K	Buy	+1,500	New	+$10K	﹤0.01%	488

Endurance Wealth Management's LOGC Position: Q4 2022 in Review

Endurance Wealth Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 1,500 shares.

Endurance Wealth Management first reported a position in LOGC in Q4 2020 and held it in 8 quarters. The position peaked at $12K in Q1 2022. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Endurance Wealth Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Endurance Wealth Management sold 1,500 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
Endurance Wealth Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Endurance Wealth Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $12K in Q1 2022.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Endurance Wealth Management's 13F filing for Q4 2022, filed 1 Feb 2023.